FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	D.C. 20549	
---------------	------------	--

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	urden							
hours per response.	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Kearney Terrence C			VI	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								Relationship of Reporting Person(s) to Iss (Check all applicable) X Director 10% Ov. Officer (give title Other (s)			ner			
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS						3. Date of Earliest Transaction (Month/Day/Year) 05/01/2023								Officer (give title Ot below) be				респу
INCORPORATED 50 NORTHERN AVENUE				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street)	N M	A	02210		Ri	ıle '	10h5-	1(c) Transa	actic	on Inc	lication		Form Perso	filed by Mor	e than O	ne Repor	ting
(City)	(Sf	ate) ((Zip)			Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - Non	-Deriv	ative	Sec	curitie	s Ac	quired, [Disp	osed c	of, or Be	neficia	ly Owne	t			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execu Day/Year) if any		execution any	. Deemed ecution Date, iny onth/Day/Year)		Transaction Dispose Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 an		Benefic Owned	es ally Following	6. Owner Form: Di (D) or In- (I) (Instr.	direct 6	7. Nature of Indirect Beneficial Ownership Instr. 4)	
								Code	v	Amount (A) or (D)		Price	Transac	Reported Fransaction(s) Instr. 3 and 4)		(1		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly Ov Fo Dii or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$342.73	05/01/2023			A		3,481		(1)	04/	/30/2033	Common Stock	3,481	\$0.00	3,481		D	

Explanation of Responses:

1. Fully vested.

Remarks:

/s/ Christiana Stevenson, 05/03/2023 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).